Predictive value of tumor mutational burden (TMB) in patients with metastatic microsatellite-stable (MSS) colorectal cancer (CRC) given first-line oxaliplatinbased chemotherapy and immune checkpoint blockade (ICB)

被引：0

|

作者：

Ree, Anne Hansen

Bousquet, Paula A.

Nilsen, Hilde L.

Luders, Torben

Wang, Shixiong

Visnovska, Tina

Bordin, Diana L.

Hoye, Eirik

Hamre, Hanne M.

Kersten, Christian

Hofsli, Eva

Guren, Marianne G.

Sorbye, Halfdan

Flatmark, Kjersti

Meltzer, Sebastian

机构：

来源：

CANCER RESEARCH | 2024年 / 84卷 / 06期

关键词：

D O I：

10.1158/1538-7445.AM2024-2522

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2522

引用

下载

收藏

页数：2

相关论文

共 33 条

[31] Sequential CPT-11 and 5FU as second-line treatment of metastatic colorectal cancer (CRC) in patients progressing after first-line 5FU-based chemotherapy.: Value of the polymorphic tandem repeat sequence of the thymidylate synthase promoter.
Abad, A
Moreno, I
Navarro, M
Manzano, JL
Alonso, J
Batista, M
Gallen, M
Centelle, M
Valentí, J
Tarón, M
ANNALS OF ONCOLOGY, 2000, 11 : 45 - 45
[32] The predictive value of single nucleotide polymorphisms in the vascular endothelial growth factor system in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy as first-line treatment: Results of the phase III ACT trial NCT00598156 translational study
Hansen, T.
Christensen, R. D.
Andersen, R. F.
Spindler, K. G.
Johnsson, A.
Jakobsen, A. K. M.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[33] Predictability of survival outcome by early tumor shrinkage (ETS) at 8 weeks with cutoff value of 20% in metastatic colorectal cancer (mCRC) patients treated with mFOLFOX6 plus bevacizumab (bev) or FOLFIRI plus bev as first-line chemotherapy (1st-CTx): Validation in the phase III WJOG4407G trial.
Sakamaki, Kentaro
Kito, Yosuke
Izawa, Naoki
Tsuda, Takashi
Morita, Satoshi
Yamazaki, Kentaro
Boku, Narikazu
Muro, Kei
Hyodo, Ichinosuke
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)

← 1 2 3 4 →